Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 3/20 | 0.44 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.44 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.44 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.44 |
| ▸ | FAP | Q12884 | 1/20 | 0.44 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | LAP3 | P28838 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10451323 | 0.82 | DPP4 (0.47) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL23975825 | 0.82 | DPP4 (0.47) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL355353 | 0.82 | DPP4 (0.47) | DPP4DPP8DPP9DPP7FAP | |
| Hydrochloric Acid SCHEMBL356236 | 0.80 | DPP4 (0.45) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL3162091 | 0.78 | DPP4 (0.44) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL27510202 | 0.78 | DPP4 (0.44) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL1233264 | 0.77 | POLB (0.33) | — | |
| SCHEMBL3206175 | 0.74 | SLC7A5 (0.41) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL3206179 | 0.74 | SLC7A5 (0.41) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL8698296 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150148394-A1 | ESTER PRO-DRUGS OF [3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL] METHANOL FOR TREATING SKIN DISEASES AND CONDITIONS | ALLERGAN INC (US) | 2015-05-28 | — | — | US | claimed |
| EP-3636263-B1 | ESTER PRO-DRUGS OF [3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL] METHANOL | ALLERGAN INC (US) | 2021-11-03 | — | — | EP | disclosed |
| CN-105412092-B | Ester prodrugs of [3- (1- (1H-imidazol-4-yl) ethyl) -2-methylphenyl ] methanol for lowering intraocular pressure | 阿勒根公司 | 2020-11-17 | — | — | CN | disclosed |
| EP-3698789-A1 | ESTER PRO-DRUGS OF [3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL] METHANOL FOR LOWERING INTRAOCULAR PRESSURE | ALLERGAN, INC. (US) | 2020-08-26 | — | — | EP | disclosed |
| EP-3659600-A1 | ESTER PRO-DRUGS OF [3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL] METHANOL FOR TREATING RETINAL DISEASES | ALLERGAN, INC. (US) | 2020-06-03 | — | — | EP | disclosed |
| EP-3636263-A1 | ESTER PRO-DRUGS OF [3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL] METHANOL | ALLERGAN, INC. (US) | 2020-04-15 | — | — | EP | disclosed |
| EP-3338777-B1 | ESTER PRO-DRUGS OF [3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL] METHANOL FOR TREATING RETINAL DISEASES | ALLERGAN INC (US) | 2020-02-05 | — | — | EP | disclosed |
| EP-3050564-B1 | ESTER PRO-DRUGS OF [3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL] METHANOL | ALLERGAN INC (US) | 2019-09-04 | — | — | EP | disclosed |
| EP-3078376-B1 | ESTER PRO-DRUGS OF [3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL] METHANOL FOR TREATING RETINAL DISEASES | ALLERGAN INC (US) | 2019-03-27 | — | — | EP | disclosed |
| EP-3348264-A1 | ESTER PRO-DRUGS OF [3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL] METHANOL FOR LOWERING INTRAOCULAR PRESSURE | ALLERGAN, INC. (US) | 2018-07-18 | — | — | EP | disclosed |
| US-8492557-B2 | Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol | ALLERGAN, INC. (US) | 2013-07-23 | — | — | US | disclosed |
| US-8492422-B2 | Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating skin diseases and conditions | ALLERGAN, INC. (US) | 2013-07-23 | — | — | US | disclosed |
| US-20120149746-A1 | ESTER PRO-DRUGS OF [3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL] METHANOL FOR TREATING RETINAL DISEASES | ALLERGAN, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120142746-A1 | ESTER PRO-DRUGS OF [3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL] METHANOL FOR LOWERING INTRAOCULAR PRESSURE | ALLERGAN, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120136036-A1 | ESTER PRO-DRUGS OF [3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL] METHANOL FOR TREATING SKIN DISEASES AND CONDITIONS | ALLERGAN, INC. (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120122945-A1 | ESTER PRO-DRUGS OF [3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL] METHANOL | ALLERGAN, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| WO-2012037453-A1 | ESTER PRO-DRUGS OF [3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL] METHANOL FOR TREATING RETINAL DISEASES | ALLERGAN, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| WO-2012037490-A1 | ESTER PRO-DRUGS OF [3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL] METHANOL FOR LOWERING INTRAOCULAR PRESSURE | ALLERGAN, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| WO-2012037499-A1 | ESTER PRO-DRUGS OF [3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL] METHANOL | ALLERGAN, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| WO-2012037484-A1 | ESTER PRO-DRUGS OF [3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL] METHANOL FOR TREATING SKIN DISEASES AND CONDITIONS | ALLERGAN, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142746-A1 | ESTER PRO-DRUGS OF [3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL] METHANOL FOR LOWERING INTRAOCULAR PRESSURE | REN, CYP11B2, PDE3A | DPP4 246/4885DPP8 448/4885DPP9 269/4885 |
| US-20120136036-A1 | ESTER PRO-DRUGS OF [3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL] METHANOL FOR TREATING SKIN DISEASES AND CONDITIONS | TYR, EBP, CUTA | DPP4 548/4885DPP8 1328/4885DPP9 855/4885 |
| US-20150148394-A1 | ESTER PRO-DRUGS OF [3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL] METHANOL FOR TREATING SKIN DISEASES AND CONDITIONS | TYR, EBP, CUTA | DPP4 548/4885DPP8 1328/4885DPP9 855/4885 |
| US-20120149746-A1 | ESTER PRO-DRUGS OF [3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL] METHANOL FOR TREATING RETINAL DISEASES | PDE6D, ALDH1A2, PDE6A | DPP4 167/4885DPP8 733/4885DPP9 361/4885 |
| US-20120122945-A1 | ESTER PRO-DRUGS OF [3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL] METHANOL | ADRB3, ADRB1, ADRB2 | DPP4 372/4885DPP8 737/4885DPP9 805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.